Satellos Bioscience GAAP EPS of -$1.70

What: Satellos Bioscience reported a GAAP EPS of -$1.70, indicating significant net losses.
Why: The company's net losses are likely due to high research and development expenses, as well as investments in its pipeline of treatments.
Signal: This EPS result suggests that the company is still in the early stages of development and may require additional funding to achieve profitability.
Target: Investors may be looking for Satellos Bioscience to achieve a GAAP EPS of $0.50 or higher within the next two years, indicating a significant improvement in profitability.
Risk: The company's reliance on a single product candidate and its high burn rate pose significant risks to its long-term viability.